Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Altres ajuts: This trial was funded by Eli Lilly and Company. The online version of this article contains supplementary material, which is available to authorized users.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wick, Antje, Desjardins, Annick, Suárez, Cristina, Forsyth, Peter, Gueorguieva, Ivelina, Burkholder, Tiana, Cleverly, Ann Louise, Estrem, Shawn T, Wang, Shuaicheng, Lahn, Michael M, Guba, Susan C, Capper, David, Rodon Ahnert, Jordi, Universitat Autònoma de Barcelona
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Galunisertib
Glioblastoma
Radiochemotherapy
T cells
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Altres ajuts: This trial was funded by Eli Lilly and Company. The online version of this article contains supplementary material, which is available to authorized users.